Details for: IGLV3 10

Gene ID: 28803

Gene Type:  Other  - A known gene or region type that lacks a specific category. Includes immunoglobulin (Ig), T-cell receptor (TCR) gene segments, and repetitive elements.

Symbol: IGLV3 10

Ensembl ID: ENSG00000211669

Description: immunoglobulin lambda variable 3-10

Cell Significance Landscape

Associated with

Significant Cells

Cell Significance Index (CSI) scores for the chosen context(s)

  • IgA plasma cell CL0000987
    CSI 4.02
    rCSI 4.11%
    PRS 97.93
  • CD4-positive, alpha-beta T cell CL0000624
    CSI 3.87
    rCSI 4.95%
    PRS 97.42
  • plasmablast CL0000980
    CSI 3.53
    rCSI 2.78%
    PRS 98.9
  • IgG plasma cell CL0000985
    CSI 3.03
    rCSI 3.63%
    PRS 98.88

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration

Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.

Comma-separated if multiple.
Comma-separated if multiple.
Legend:
  • Query Gene
  • Node Color (Target Cell CSI, relative to current network):
    • Very High
    • High
    • Medium
    • Low
    • Very Low
    • CSI N/A
  • Node Size: Proportional to Target Cell CSI magnitude
  • STRING PPI Edge
  • Shared Pathway Edge (ONTOLOGY)

Loading network (please wait)...

Other Information

This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.

## Summary [IGLV3 10](/details-gene/28803) is a gene encoding the immunoglobulin lambda variable 3-10 segment, a component of the antibody light chain. As a variable (V) gene segment, it plays a crucial role in the combinatorial and junctional diversity of the B-cell receptor and secreted antibodies. Functional annotation places it centrally within the [Adaptive immune response](/details-cell/GO:0002250), where it contributes to the formation of the [Immunoglobulin complex](/details-cell/GO:0019814). Expression data indicates its primary significance in late-stage B-lymphocyte lineage cells, particularly antibody-secreting cells such as [IgA plasma cell](/details-cell/CL0000987)s and [plasmablast](/details-cell/CL0000980)s, underscoring its fundamental role in humoral immunity. ## Cellular Roles and Expression Landscape The expression profile of [IGLV3 10](/details-gene/28803) firmly establishes its identity as a key genetic component for the effector phase of the humoral immune response. **Overall**, the gene shows the highest significance in cells dedicated to antibody production. Its most prominent expression is observed in: * **[IgA plasma cell](/details-cell/CL0000987)** (CSI: 4.02) * **[plasmablast](/details-cell/CL0000980)** (CSI: 3.53) * **[IgG plasma cell](/details-cell/CL0000985)** (CSI: 3.03) This pattern highlights its importance in terminally differentiated B-cells that are actively secreting immunoglobulins. The high significance in both IgA- and IgG-producing plasma cells suggests its V-segment can be utilized in antibodies produced after class-switching, which are critical for mucosal and systemic immunity, respectively. The gene also shows high significance in [CD4-positive, alpha-beta T cell](/details-cell/CL0000624)s (CSI: 3.87), which may reflect transcriptional noise, cell-cell contamination in datasets, or a less characterized role; however, its canonical function is restricted to the B-cell lineage. ## Pathways and Molecular Function The molecular function of [IGLV3 10](/details-gene/28803) is intrinsically linked to its role as a building block for antibodies. Gene Ontology annotations confirm its participation in the broad biological process of the [Immune response](/details-cell/GO:0006955) and, more specifically, the [Adaptive immune response](/details-cell/GO:0002250). At the molecular level, the protein segment encoded by [IGLV3 10](/details-gene/28803) is an integral part of the [Immunoglobulin complex](/details-cell/GO:0019814), which is typically anchored to the [Plasma membrane](/details-cell/GO:0005886) in the form of the B-cell receptor or secreted as a soluble antibody. The diversity generated by V(D)J recombination, which involves segments like [IGLV3 10](/details-gene/28803), is essential for creating a vast repertoire of antibodies capable of recognizing a near-infinite array of foreign antigens. This function is directly consistent with its high expression in plasma cells, the body's primary antibody factories. ## Research Directions The specific usage of particular immunoglobulin variable gene segments can have significant implications in both health and disease, offering avenues for biomarker discovery and therapeutic targeting. **Proposed Hypotheses:** 1. *Hypothesis on Autoimmunity:* Preferential usage of the [IGLV3 10](/details-gene/28803) gene segment, potentially with specific somatic hypermutations, may be a feature of pathogenic autoantibodies in certain autoimmune conditions, such as lupus or Sjögren's syndrome. This could arise from its inherent structural properties that favor binding to self-antigens. 2. *Hypothesis on Malignancy:* The clonal B-cell populations characteristic of hematological malignancies, like multiple myeloma or chronic lymphocytic leukemia, may exhibit biased or over-represented usage of [IGLV3 10](/details-gene/28803). This over-representation could serve as a prognostic biomarker or indicate a common pathogenic origin. **Experimental Approach:** To test the hypothesis regarding malignancy (Hypothesis 2), one could perform B-cell receptor repertoire sequencing (BCR-seq) on bone marrow aspirates from a large cohort of multiple myeloma patients. By analyzing the V-gene segment usage frequency within the malignant [plasma cell](/details-cell/CL0000987) population and comparing it to the repertoire of healthy donor [plasma cell](/details-cell/CL0000987)s, researchers could determine if [IGLV3 10](/details-gene/28803) is significantly enriched. Any observed enrichment could then be correlated with clinical parameters such as disease stage, treatment response, and overall survival. **Therapeutic Potential:** [IGLV3 10](/details-gene/28803) itself is not a direct drug target, as it is a germline DNA segment. However, the unique antibody idiotype it helps create in a clonal disease (e.g., a B-cell lymphoma) represents a highly specific tumor antigen. If a malignancy is defined by a clone utilizing [IGLV3 10](/details-gene/28803), it could be targeted with precision therapies. These include anti-idiotype monoclonal antibodies or chimeric antigen receptor (CAR) T-cell therapies engineered to recognize the specific antigen-binding site formed by the [IGLV3 10](/details-gene/28803)-containing light chain. This would be an inhibition-based strategy aimed at eradicating the malignant clone with minimal off-target effects.